Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Stanley D. Glick, and Jamon Alexander Rahn in 2019 and is headquarter in Toronto, Canada.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol MNMD.
This company has cross-listed shares that trade in the U.S. as the symbol MNMD.
0.00
As of 01/29/2023
2022 © Stock Market MBA, Inc.